Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)

被引：0
|
作者：
S G Louie
B Ely
H-J Lenz
K S Albain
C Gotay
D Coleman
D Raghavan
A F Shields
P J Gold
C D Blanke
机构：
[1] University of Southern California,Department of Pharmacy
[2] Norris Comprehensive Cancer Center,Department of Oncology
[3] Loyola University Chicago/Cardinal Bernardin Cancer Center,undefined
[4] University of British Columbia,undefined
[5] Cancer Research Center of Hawaii,undefined
[6] Carolinas Medical Center/Levine Cancer Institute,undefined
[7] Karmanos Cancer Institute/Wayne State University,undefined
[8] Swedish Cancer Institute,undefined
[9] Knight Cancer Institute and SWOG,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
elderly; pharmacokinetics; colorectal cancer; capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1744 / 1749
页数：5
相关论文
共 50 条
  • [41] XELOX (capecitabine and axaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).
    Salud, A
    Escudero, P
    Feliú, J
    López-Gómez, L
    Bolanos, M
    Galán, A
    Yubero, A
    Vicent, JM
    Losa, F
    Barón, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 276S - 276S
  • [42] Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer
    Abdi, Z. Daher
    Lavau-Denes, S.
    Premaud, A.
    Urien, S.
    Sauvage, F. L.
    Martin, J.
    Leobon, S.
    Marquet, P.
    Tubiana-Mathieu, N.
    Rousseau, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1285 - 1293
  • [43] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [44] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [45] Elderly patients with advanced colorectal cancer: Tolerability and activity of chemotherapy
    Berardi, R
    Saladino, T
    Mari, D
    Silva, RR
    Scartozzi, M
    Verdecchia, L
    Onofri, A
    Cascinu, S
    TUMORI, 2005, 91 (06) : 463 - 466
  • [46] ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER: EFFICACY OF THE FOLFOX REGIMEN
    Bearz, A.
    Berretta, M.
    Buonadonna, A.
    La Mura, N.
    Spina, M.
    Talamini, R.
    Tirelli, U.
    Frustaci, S.
    ANNALS OF ONCOLOGY, 2004, 15 : 64 - 65
  • [47] Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Barletta, M. T.
    Baldi, G. G.
    Vasile, E.
    Fornaro, L.
    Petrini, I.
    Allegrini, G.
    Antonuzzo, A.
    Di Marsico, R.
    Andreuccetti, M.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [48] A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer
    Maroun, Jean
    Marginean, Horia
    Jonker, Derek
    Cripps, Christine
    Goel, Rakesh
    Asmis, Timothy
    Goodwin, Rachel
    Chiritescu, Gabriela
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E257 - E268
  • [49] A Phase I/II Study of Trimetrexate and Capecitabine in Patients With Advanced Refractory Colorectal Cancer
    Matin, K
    Jacobs, SA
    Richards, T
    Wong, MK
    Earle, M
    Evans, T
    Troetschel, M
    Ferri, W
    Friedland, D
    Pinkerton, R
    Volkin, R
    Wieand, S
    Ramanathan, RK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (05): : 439 - 444
  • [50] Capecitabine in combination with mitomycin C as third line chemotherapy in patients with advanced colorectal cancer
    Ritorto, G.
    Fanchini, L.
    Racca, P.
    Evangelista, W.
    Volpatto, R.
    Angelini, F.
    Ciuffreda, L.
    Ottaviani, D.
    Bertetto, O.
    ANNALS OF ONCOLOGY, 2005, 16 : 46 - 46
12345